Thymosin Alpha-1 is not approved by the U.S. FDA and has been flagged by the FDA as a substance that may present significant safety risks. It is not lawful to compound or administer to humans.
Status as of July 15, 2026
Thymosin alpha-1, sold outside the United States as the pharmaceutical thymalfasin, is delivered by subcutaneous injection from a freeze-dried powder reconstituted immediately before use. The dose cited most consistently across the published record is 1.6 mg given twice weekly, the schedule that carried the chronic hepatitis B and C trials making up most of the clinical evidence. That figure describes how an approved-abroad, quality-assured drug was studied under physician direction, not a recipe that transfers to material sold through unregulated channels in the US.
The reference regimen documented across the clinical literature is 1.6 mg of thymalfasin injected subcutaneously twice weekly under physician supervision, a schedule established in chronic hepatitis B and C trials of an approved-abroad drug that is not FDA-approved in the United States.
The studied form is given subcutaneously, into the fatty tissue just beneath the skin, because thymosin alpha-1 is a 28-amino-acid peptide that stomach acid and digestive proteases would break down before it reached the bloodstream if taken by mouth. Subcutaneous delivery also produces slower, more sustained uptake than an intravenous push, which suits the twice-weekly trial schedule. The intramuscular and intravenous routes are not the standard described approach; the clinical record is built around subcutaneous dosing.
Thymosin alpha-1 is documented as a subcutaneously injected agent because its 28-amino-acid peptide structure is destroyed by oral digestion, and the clinical literature is built around subcutaneous rather than intramuscular or intravenous dosing.
The regimen reported most often is 1.6 mg subcutaneously twice weekly, a figure that comes primarily from the chronic hepatitis B and C studies where it was frequently paired with or compared against interferon-based therapy. The two injections are typically spaced across the week, roughly every three to four days, and the dose is described as a fixed amount rather than one calculated per kilogram of body weight for the adult hepatitis regimen. Investigational work in other areas has explored different amounts and frequencies, but none displaces the twice-weekly 1.6 mg schedule as the commonly cited baseline.
The most commonly reported regimen is a fixed 1.6 mg dose given subcutaneously twice weekly, spaced roughly every three to four days, drawn primarily from the chronic hepatitis B and C trials rather than a per-kilogram calculation.
The freeze-dried powder must be dissolved before it can be drawn into a syringe, and the published preparation procedure treats the peptide as fragile. The diluent is directed gently against the inside wall of the vial rather than sprayed onto the powder, and the vial is swirled rather than shaken, steps described to avoid damaging the peptide and to limit foaming. Because the reconstituted solution carries no strong preservative, the record describes it as intended for prompt use rather than storage.
Published preparation procedures describe reconstituting the vial with a small measured volume of sterile diluent directed against the glass wall, swirling rather than shaking to protect the peptide, and using the solution promptly because it contains no robust preservative.
The sealed lyophilized powder is generally stored refrigerated, commonly cited around 2 to 8 degrees Celsius, and kept in its carton to limit light exposure. The freeze-dried form is more stable than a solution, which is why the drug is supplied as a powder reconstituted at the point of use, but it is still handled as a temperature-sensitive biologic that is not frozen or left in heat. Once reconstituted, the solution has a much shorter usable window and is meant to be injected soon after mixing.
The sealed powder is documented as refrigerated storage at roughly 2 to 8 degrees Celsius protected from light and freezing, while material bought through informal channels carries storage history no one can verify, undermining any assumption about its remaining potency.
In the chronic hepatitis studies that anchor the dosing record, courses commonly ran for roughly six months of twice-weekly injections, with some protocols extending longer depending on design and the response being tracked. The course is best understood as a defined treatment period tied to the condition under study and set within the trial protocol, not an open-ended regimen. Investigational uses outside chronic hepatitis have used shorter or differently structured schedules suited to their own endpoints, so there is no single universal duration.
In the anchoring chronic hepatitis trials the treatment course typically ran about six months of twice-weekly injections, a duration bounded and defined in advance by the study protocol rather than an open-ended, self-selected timeline.
Clinical use is documented as ongoing physician oversight rather than a set-and-forget injection schedule. In the hepatitis setting this meant periodic laboratory review of liver enzymes, viral markers, and blood counts to follow both the disease and the patient's tolerance, with the prescriber first evaluating the diagnosis and baseline labs before dosing began. This monitoring layer is part of why the studied regimen produced interpretable results, and it is precisely what is absent when a product is used without clinical supervision.
The studied regimen was accompanied by physician oversight including baseline evaluation, periodic laboratory review of liver enzymes, viral markers, and blood counts, and response assessment against defined endpoints, the supervision layer absent when a product is used without clinical monitoring.
Dosing is not perfectly uniform across every use, though the twice-weekly 1.6 mg chronic hepatitis schedule dominates and is the most standardized. Investigational work in areas such as adjunctive vaccine response, certain cancers, or critically ill patients has used different amounts, frequencies, and course lengths suited to those endpoints. Because the drug is cleared as a peptide, the literature does not center on elaborate dose reductions for organ function, and body weight is generally not the basis of the fixed adult hepatitis dose.
| Dimension | Chronic hepatitis regimen | Investigational uses |
|---|---|---|
| Dose | Fixed 1.6 mg | Varies by endpoint |
| Frequency | Twice weekly | Different frequencies reported |
| Course length | About six months | Shorter or differently structured |
| Basis | Fixed, not per kilogram | Set by study rationale |
The fixed twice-weekly 1.6 mg chronic hepatitis schedule is the most standardized regimen, while investigational uses in vaccine adjuvant, oncology, and critical-care settings have documented different doses, frequencies, and course lengths matched to their own endpoints rather than a fixed conversion formula.
The dosing figures that make sense for a verified pharmaceutical lose their meaning when the product itself is unverified. Because thymosin alpha-1 is not FDA-approved in the United States, material sold through research-chemical or gray-market channels is not manufactured or tested to pharmaceutical standards, so the milligram amount on the label may not match the vial's actual content, which can be under-strength, over-strength, degraded, or a different substance entirely. Measuring 1.6 mg from a source whose true concentration is unknown reproduces the number, not the studied dose.
Because thymosin alpha-1 is not FDA-approved and gray-market product is untested for identity, potency, purity, and sterility, measuring 1.6 mg from such a source reproduces only the number and not the studied dose, stripping away the physician oversight that gave the trial figures their validity.
Educational use only. This article describes what the published scientific and clinical literature reports about Thymosin Alpha-1. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
